Bevacizumab formulations with lower aggregation propensity, comprising corticosteroid anti-inflammatory drugs
The present invention is directed to combination formulations of monoclonal antibodies with anti-inflammatory agents, related methods and uses thereof.
1. A stable antibody formulation said formulation comprising an aqueous carrier, bevacizumab and a corticosteroid anti-inflammatory drug selected from dexamethasone, dexamethasone sodium phosphate, a dexamethasone derivative, betamethasone, betamethasone sodium phosphate, or a pharmaceutically acceptable salt thereof, wherein corticosteroid anti-inflammatory drug to bevacizumab-molar ratio ranges from is 1.53:1 to 153:1 and the dexamethasone derivative is of Formula (I):
wherein R 1 is selected from H, halogen, —OH, —O 4 PHNa 2 , —O—C(O)—R 9 ; R 2 is selected from H, OH, —O—C(O)—R 10 ; R 3 is selected from H or —CH 3 ; R 4 is selected from H, and halogen; R 5 is selected from H, OH and carbonyl; R 6 and R 7 are H or form together a double bond; R 8 is selected from optionally substituted C 1 -C 6 alkyl and optionally substituted acetyl; R 9 and R 10 are independently selected from optionally substituted C 1 -C 6 alkyl and optionally substituted C 3 -C 8 -cycloalkyl; R 11 is selected from H or optionally substituted C 1 -C 6 alkyl.
2. The formulation according to claim 1 , wherein the formulation is a pharmaceutical formulation.
3. The formulation according to claim 1 wherein said corticosteroid anti-inflammatory drug is: a) dexamethasone or a derivative thereof; or b) betamethasone, wherein the dexamethasone derivative is of Formula (I):
wherein R 1 is selected from H, halogen, —OH, —O 4 PHNa 2 , —O—C(O)—R 9 ; R 2 is selected from H, OH, —O—C(O)—R 10 ; R 3 is selected from H or —CH 3 ; R 4 is selected from H, and halogen; R 5 is selected from H, OH and carbonyl; R 6 and R 7 are H or form together a double bond; R 8 is selected from optionally substituted C 1 -C 6 alkyl and optionally substituted acetyl; R 9 and R 10 are independently selected from optionally substituted C 1 -C 6 alkyl and optionally substituted C 3 -C 8 -cycloalkyl; R 11 is selected from H or optionally substituted C 1 -C 6 alkyl.
4. The formulation according to claim 3 wherein said corticosteroid anti-inflammatory drug is dexamethasone.
5. The formulation according to claim 3 wherein said corticosteroid anti-inflammatory drug is betamethasone.
6. The formulation according to claim 1 wherein the formulation has a pH in the range between pH 4.5 and pH 7.5.
7. The formulation according to claim 1 , further comprising an excipient.
8. A pharmaceutical unit dosage form suitable for ocular administration to a mammal comprising an antibody formulation according to claim 1 in a suitable container.
9. A method of stabilizing bevacizumab in aqueous solution comprising combining bevacizumab with a corticosteroid anti-inflammatory drug, wherein said corticosteroid anti-inflammatory drug is selected from dexamethasone, dexamethasone sodium phosphate, a dexamethasone derivative, betamethasone, betamethasone sodium phosphate or pharmaceutically acceptable salts thereof, wherein the dexamethasone derivative is of Formula (I):
wherein R 1 is selected from H, halogen, —OH, —O 4 PHNa 2 , —O—C(O)—R 9 ; R 2 is selected from H, OH, —O—C(O)—R 10 ; R 3 is selected from H or —CH 3 ; R 4 is selected from H, and halogen; R 5 is selected from H, OH and carbonyl; R 6 and R 7 are H or form together a double bond; R 8 is selected from optionally substituted C 1 -C 6 alkyl and optionally substituted acetyl; R 9 and R 10 are independently selected from optionally substituted C 1 -C 6 alkyl and optionally substituted C 3 -C 8 -cycloalkyl; R 11 is selected from H or optionally substituted C 1 -C 6 alkyl and the corticosteroid anti-inflammatory drug to bevacizumab molar ratio ranges from 1.53:1 to 153:1.
10. The method according to claim 9 wherein said corticosteroid anti-inflammatory drug is dexamethasone or a derivative thereof.
11. The method according to claim 10 wherein the corticosteroid anti-inflammatory drug is betamethasone.
12. A process for the preparation of a bevacizumab formulation comprising the steps of:
(i) combining bevacizumab with a corticosteroid anti-inflammatory drug into a liquid mixture or forming a formulation comprising bevacizumab and a liquid medium containing a corticosteroid anti-inflammatory drug, said corticosteroid anti-inflammatory drug selected from dexamethasone, dexamethasone sodium phosphate, a dexamethasone derivative, betamethasone, betamethasone sodium phosphate or pharmaceutically acceptable salts of and wherein the dexamethasone derivative is of Formula (I):
wherein R 1 is selected from H, halogen, —OH, —O 4 PHNa 2 , —O—C(O)—R 9 ; R 2 is selected from H, OH, —O—C(O)—R 10 ; R 3 is selected from H or —CH 3 ; R 4 is selected from H, and halogen; R 5 is selected from H, OH and carbonyl; R 6 and R 7 are H or form together a double bond; R 8 is selected from optionally substituted C 1 -C 6 alkyl and optionally substituted acetyl; R 9 and R 10 are independently selected from optionally substituted C 1 -C 6 alkyl and optionally substituted C 3 -C 8 -cycloalkyl; R 11 is selected from H or optionally substituted C 1 -C 6 alkyl and the corticosteroid anti-inflammatory drug to bevacizumab molar ratio ranges from 1.53:1 to 153:1; and
formulation obtained under step (i.
13. The process according to claim 12 wherein said corticosteroid anti-inflammatory drug is dexamethasone or a derivative thereof.
14. The process according to claim 13 wherein said corticosteroid anti-inflammatory drug is betamethasone.
15. A method of inhibiting the biological activity of vascular endothelial growth factor (VEGF) in a subject comprising administering to a subject having a disease or a disorder selected from a cancer, a neovascular age-related macular degeneration disease (AMD) and a disorder associated with AMD a therapeutically effective amount of a stable antibody formulation according to claim 1 .
16. The stable antibody formulation according to claim 1 , wherein less than 10% of antibody in said formulation forms an aggregate during storage at 40° C. for 35 days, as determined by multi-angle light scattering (MALS) coupled to asymmetrical flow field-flow fractionation (AFFF).
17. The stable antibody formulation according to claim 16 , wherein said formulation comprises bevacizumab and dexamethasone.
18. The stable antibody formulation according to claim 1 , wherein the corticosteroid anti-inflammatory drug is at a concentration in the range of about 0.1 mg/ml to about 13 mg/ml.
19. The stable antibody formulation according to claim 1 , wherein bevacizumab is at a concentration in the range of about 5 mg/ml to about 100 mg/ml.